These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 10196523)

  • 1. Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau.
    Hardy J; Duff K; Hardy KG; Perez-Tur J; Hutton M
    Nat Neurosci; 1998 Sep; 1(5):355-8. PubMed ID: 10196523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The amyloid and tau hypothesis in degenerative dementia].
    Fladby T; Maehlen J
    Tidsskr Nor Laegeforen; 1999 Mar; 119(7):976-9. PubMed ID: 10210960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurodegeneration and Alzheimer's disease: the lesson from tauopathies.
    Sorrentino G; Bonavita V
    Neurol Sci; 2007 Apr; 28(2):63-71. PubMed ID: 17464468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease: beta-Amyloid protein and tau.
    Morishima-Kawashima M; Ihara Y
    J Neurosci Res; 2002 Nov; 70(3):392-401. PubMed ID: 12391602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease.
    Formichi P; Battisti C; Radi E; Federico A
    J Cell Physiol; 2006 Jul; 208(1):39-46. PubMed ID: 16447254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).
    Koopman K; Le Bastard N; Martin JJ; Nagels G; De Deyn PP; Engelborghs S
    Neurochem Int; 2009 Sep; 55(4):214-8. PubMed ID: 19524111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau is central in the genetic Alzheimer-frontotemporal dementia spectrum.
    Dermaut B; Kumar-Singh S; Rademakers R; Theuns J; Cruts M; Van Broeckhoven C
    Trends Genet; 2005 Dec; 21(12):664-72. PubMed ID: 16221505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Advances in molecular biology and clinical study of amyloid precursor protein for Alzheimer's disease].
    Xu BG; Wu X
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Apr; 26(2):201-9. PubMed ID: 15171563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice.
    Ribé EM; Pérez M; Puig B; Gich I; Lim F; Cuadrado M; Sesma T; Catena S; Sánchez B; Nieto M; Gómez-Ramos P; Morán MA; Cabodevilla F; Samaranch L; Ortiz L; Pérez A; Ferrer I; Avila J; Gómez-Isla T
    Neurobiol Dis; 2005 Dec; 20(3):814-22. PubMed ID: 16125396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-tau based neuronal degeneration in Alzheimer's disease -- an immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex.
    van de Nes JA; Nafe R; Schlote W
    Brain Res; 2008 Jun; 1213():152-65. PubMed ID: 18455153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of tau (MAPT) in frontotemporal dementia and related tauopathies.
    Rademakers R; Cruts M; van Broeckhoven C
    Hum Mutat; 2004 Oct; 24(4):277-95. PubMed ID: 15365985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.
    Hardy J; Selkoe DJ
    Science; 2002 Jul; 297(5580):353-6. PubMed ID: 12130773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial dysfunction in sporadic and genetic Alzheimer's disease.
    Hauptmann S; Keil U; Scherping I; Bonert A; Eckert A; Müller WE
    Exp Gerontol; 2006 Jul; 41(7):668-73. PubMed ID: 16677790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders.
    Ballatore C; Lee VM; Trojanowski JQ
    Nat Rev Neurosci; 2007 Sep; 8(9):663-72. PubMed ID: 17684513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes.
    David DC; Ittner LM; Gehrig P; Nergenau D; Shepherd C; Halliday G; Götz J
    Proteomics; 2006 Dec; 6(24):6566-77. PubMed ID: 17111439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights from Drosophila models of Alzheimer's disease.
    Cowan CM; Shepherd D; Mudher A
    Biochem Soc Trans; 2010 Aug; 38(4):988-92. PubMed ID: 20658990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
    Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
    Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alzheimer's disease and the 'ABSENT' hypothesis: mechanism for amyloid beta endothelial and neuronal toxicity.
    Roy S; Rauk A
    Med Hypotheses; 2005; 65(1):123-37. PubMed ID: 15893129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isoaspartate formation and neurodegeneration in Alzheimer's disease.
    Shimizu T; Watanabe A; Ogawara M; Mori H; Shirasawa T
    Arch Biochem Biophys; 2000 Sep; 381(2):225-34. PubMed ID: 11032409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.